TGTX TG Therapeutics, Inc.
Price Chart
Executive Summary
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokinetics, safety, and tolerability. The quarterly subcutaneous dosing regimen achieved modeled non-inferior drug exposure vs. IV BRIUMVI, supporting the ongoing Phase 3 trial with topline data expected late 2026 or early 2027. If approved, subcutaneous BRIUMVI could be the first self-administered quarterly anti-CD20 therapy for MS, potentially nearly doubling the addressable market.
Actionable Insight
The positive Phase 1 data de-risks the subcutaneous BRIUMVI program and supports the ongoing Phase 3 trial. Traders should monitor for Phase 3 topline results (late 2026/early 2027) and any device bridging study updates later this year. The potential for a self-administered quarterly anti-CD20 therapy could significantly expand TGTX's total addressable market, making this a key catalyst to watch.
Key Facts
- Phase 1 trial of subcutaneous BRIUMVI showed mean bioavailability >60% vs. IV, with lower bound of 95% CI exceeding 55%.
- PK modeling supports non-inferior total drug exposure over 24 weeks for quarterly dosing (GMR 1.21, lower bound 90% CI 1.15) and every-other-month dosing (GMR 1.58, lower bound 90% CI 1.50), both exceeding the non-inferiority threshold of 0.80.
- Subcutaneous BRIUMVI was well-tolerated; local injection-site reactions occurred in <5% of patients, systemic injection-related reactions in ~21%, all resolved, no serious injection-site reactions or new safety signals.
- Phase 3 trial fully enrolled; topline results expected late 2026 or early 2027; potential approval in 2028 if successful.
- CEO stated subcutaneous option could nearly double the addressable market for the BRIUMVI franchise.
- Over 100 patients treated in Phase 1, including >80 receiving subcutaneous BRIUMVI across multiple dose levels; >225 subcutaneous injections administered, >75% at 400 mg (2 mL).
Financial Impact
No financial figures provided; potential market expansion from subcutaneous BRIUMVI could nearly double the BRIUMVI franchise addressable market if approved.
Risk Factors
- Phase 3 trial may fail to meet primary endpoint despite positive Phase 1 data.
- Regulatory approval not guaranteed; timeline to potential approval in 2028 is subject to delays or rejection.
- Commercial adoption of subcutaneous BRIUMVI may be lower than anticipated, limiting market expansion.
- Competition from existing and emerging MS therapies could erode market share.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $48.03 awaiting T+1 | awaiting T+1 | — | $49.52 (+3.10%) |
|
Jun 3, 2026
9d ago
|
8-K
| $40.11 $40.56 | ▲ +1.12% | ▲ +0.72% | $49.52 (+23.46%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $40.11 $40.56 | ▲ +1.12% | ▲ +0.72% | $49.52 (+23.46%) |
|
Jun 1, 2026
11d ago
|
Press Release
| $37.41 $36.64 | ▼ −2.06% | ▼ −2.20% | $49.52 (+32.37%) |
|
May 27, 2026
16d ago
|
8-K
| $38.82 $37.94 | ▼ −2.27% | ▼ −2.51% | $49.52 (+27.56%) |
|
May 6, 2026
5w ago
|
8-K
| $41.97 $43.03 | ▲ +2.51% | ▲ +2.84% | $49.52 (+17.99%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $33.78 $33.85 | ▲ +0.21% | ▼ −0.01% | $49.52 (+46.60%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $38.31 $36.92 | ▼ −3.63% | ▼ −3.23% | $49.52 (+29.26%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $34.60 $34.30 | ▼ −0.87% | ▼ −1.12% | $49.52 (+43.12%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $30.36 $30.07 | ▼ −0.96% | ▲ +0.79% | $49.52 (+63.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access